Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trialFrederick J. Raal, Stanley T. Crooke, Raúl D. Santos et al.|The Lancet|2010Cited by 905
Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry diseaseDominique P. Germain, William R. Wilcox, Joel Charrow et al.|Journal of Medical Genetics|2015Cited by 363
The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 1: the initial presentationStefan Kölker, Nicholas J. Thompson, Ángeles García Cazorla et al.|Journal of Inherited Metabolic Disease|2015Cited by 248
Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled PeriodAnthony A. Portale, Karl Insogna, Thomas O. Carpenter et al.|Calcified Tissue International|2019Cited by 160
A randomized, placebo-controlled clinical trial evaluating olipudase alfa enzyme replacement therapy for chronic acid sphingomyelinase deficiency (ASMD) in adults: One-year resultsMelissa Wasserstein, Monica Kumar, Robin Lachmann et al.|Genetics in Medicine|2022Cited by 99